United Therapeutics (UTHR) Cash from Financing Activities (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Cash from Financing Activities data on file, last reported at -$1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 1482.52% year-over-year to -$1.5 billion; the trailing twelve-month figure through Mar 2026 stood at -$2.5 billion (down 805.42% YoY), and the FY2025 full-year result was -$1.2 billion, up 8.35% from the prior year.
• Cash from Financing Activities slipped to -$1.5 billion in Q1 2026, from $98.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $98.4 million in Q4 2025 to a low of -$1.5 billion in Q1 2026.
• A 5-year average of -$225.0 million and a median of -$48.0 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities soared 640.0% in 2022 and sank 2297.53% in 2024, its largest moves.
• Tracing UTHR's Cash from Financing Activities over 5 years: stood at $55.5 million in 2022, then slumped by 267.21% to -$92.8 million in 2023, then grew by 19.5% to -$74.7 million in 2024, then surged by 231.73% to $98.4 million in 2025, then plunged by 1608.54% to -$1.5 billion in 2026.
• Business Quant data shows UTHR's Cash from Financing Activities at -$1.5 billion in Q1 2026, $98.4 million in Q4 2025, and -$956.0 million in Q3 2025.